https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-03 / J Clin Oncol 36, 2018 (suppl; abstr 5509)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-03 / J Clin Oncol 36, 2018 (suppl; abstr 5509)2018-06-03 10:28:302019-07-17 11:18:19Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-03 / J Clin Oncol 36, 2018 (suppl; abstr 9051)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-03 / J Clin Oncol 36, 2018 (suppl; abstr 9051)2018-06-03 00:00:002018-06-03 00:00:00Dendritic-cell vaccine (DCVAC) with first line chemotherapy in patients with stage IV NSCLC primary analysis of phase 2, open-label, randomized, multicenter trial.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-01 / J Clin Oncol 36, 2018 (suppl; abstr e17515)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-01 / J Clin Oncol 36, 2018 (suppl; abstr e17515)2018-06-01 00:00:002018-06-01 00:00:00Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with recurrent epithelial ovarian carcinoma (EOC) after complete response (CR) to 1st-line platinum (Pt)-based ct: Primary analysis of a phase 2, open-label, randomized, multicenter trial.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-05-30 / Ther Apher Dial 2018 Jun;22(3):266-277
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-05-30 / Ther Apher Dial 2018 Jun;22(3):266-2772018-05-30 00:00:002019-02-15 08:48:15Vaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-05-29 / J Transl Med 2018 May;16(1):142
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-05-29 / J Transl Med 2018 May;16(1):1422018-05-29 00:00:002019-02-15 08:47:35First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-05-29 / Front Immunol 2018;9:727
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-05-29 / Front Immunol 2018;9:7272018-05-29 00:00:002019-02-15 08:47:36Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-05-22 / Oncol Lett 2018 Jul;16(1):1180-1188
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-05-22 / Oncol Lett 2018 Jul;16(1):1180-11882018-05-22 00:00:002019-02-15 08:51:37Dendritic cells loaded with the lysate of tumor cells infected with Newcastle Disease Virus trigger potent anti-tumor immunity by promoting the secretion of IFN-γ and IL-2 from T cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-05-17 / Oncol Lett 2018 Jul;16(1):1348-1356
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-05-17 / Oncol Lett 2018 Jul;16(1):1348-13562018-05-17 00:00:002021-05-19 14:28:20Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-05-04 / Blood 2018 Jun;131(24):2640-2650
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-05-04 / Blood 2018 Jun;131(24):2640-26502018-05-04 00:00:002019-02-15 08:45:21Vaccine therapy in hematologic malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-05-01 / Ann. Oncol. 2018 May;29(5):1312-1319
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-05-01 / Ann. Oncol. 2018 May;29(5):1312-13192018-05-01 00:00:002019-02-15 08:39:10Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
